StageAcquired | Acquired
Missing: Cell Pathways's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Cell Pathways's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Cell Pathways
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cell Pathways is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Latest Cell Pathways News
Apr 22, 2014
June 12, 2003 07:30 AM Eastern Daylight Time MELVILLE, N.Y.--( BUSINESS WIRE )--June 12, 2003--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the acquisition of Cell Pathways, Inc. became effective today in a stock-for-stock merger valued at approximately $31 million based on the average closing prices of OSI's common stock around the time of the announcement of the acquisition. Under the terms of the transaction, OSI exchanged .0567 shares of OSI common stock for each share of Cell Pathways common stock. OSI provided additional consideration in the form of a five-year contingent value right, through which each share of Cell Pathways common stock will be eligible for an additional .040 of a share of OSI common stock in the event of a filing of an NDA (new drug application) for either of the two newly-acquired clinical candidates, CP461 or Aptosyn(R) (exisulind). Through this transaction, OSI has added a technology platform designed to selectively induce apoptosis, or programmed cell death through the sustained activation of protein kinase G in pre-cancerous and cancerous cells. OSI gained two drug candidates in clinical development: CP461, a potent, second-generation molecule that is currently being evaluated in dose-ranging Phase I studies and a series of exploratory Phase II studies in chronic lymphocytic leukemia, renal cell carcinoma and prostate cancer and Aptosyn(R), an earlier-generation molecule that is currently in Phase III trials in combination with Taxotere(R) for the treatment of advanced non-small cell lung cancer. The acquisition of Cell Pathways also provides OSI with an additional oncology product, Gelclair(TM), a bioadherent oral gel that provides relief for the treatment of pain associated with oral mucositis, a debilitating side effect often seen in cancer patients undergoing radiation treatment or chemotherapy. OSI is establishing a commercial operation to support Gelclair(TM) and Novantrone(R) (mitoxantrone concentrate for injection), which the Company markets exclusively for its approved oncology indications in the United States. "The Cell Pathways apoptosis technology platform complements our existing R&D approaches in this area and provides the opportunity to advance the development of novel anti-cancer drugs which we believe may have value both as monotherapy agents and in combination with existing chemotherapy drugs or other novel, targeted agents," stated Colin Goddard, Ph.D., Chief Executive Officer of the Company. "In addition, this transaction gives us our second marketed product in Gelclair(TM), which addresses a major unmet need in cancer treatment today, that of oral mucositis. We are on schedule to re-launch both Gelclair(TM) and the recently licensed Novantrone(R) under the OSI brand later this year. " OSI Pharmaceuticals is a leading biotechnology company focused on the discovery, development and commercialization of high-quality, next-generation oncology products that both extend and improve the quality-of-life for cancer patients worldwide. OSI has a balanced pipeline of oncology drug candidates that includes both next-generation cytotoxic agents and novel mechanism-based, gene-targeted therapeutics focused in the areas of signal transduction and apoptosis. OSI's most advanced drug candidate, Tarceva(TM) (erlotinib HCl), a small-molecule inhibitor of the HER1 gene, is currently in Phase III clinical trials for lung and pancreatic cancers. OSI has a commercial presence in the U.S. oncology market where it exclusively markets Novantrone(R) (mitoxantrone concentrate for injection) for approved oncology indications. This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, the completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, the ability to effectively market products and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission. Contacts
Cell Pathways Frequently Asked Questions (FAQ)
Where is Cell Pathways's headquarters?
Cell Pathways's headquarters is located at 702 Electronic Drive, Horsham.
What is Cell Pathways's latest funding round?
Cell Pathways's latest funding round is Acquired.
How much did Cell Pathways raise?
Cell Pathways raised a total of $73.39M.
Who are the investors of Cell Pathways?
Investors of Cell Pathways include OSI Pharmaceuticals, Jackson Boulevard Capital Management, Morgan Stanley, Coutts, Cercano Management and 10 more.
Who are Cell Pathways's competitors?
Competitors of Cell Pathways include La Jolla Pharmaceutical Company, Minerva Biotechnologies, Animal Cell Therapies, Keryx Biopharmaceuticals, ProCertus BioPharm and 12 more.
Compare Cell Pathways to Competitors
Minerva Biotechnologies developd biochips: nanoparticles coated with functionalized affinity surfaces. Minerva has developed user-friendly nanoparticles that the end user can utilize as a "black box technology". The nanoparticle system can be fully automated and a range of nanoparticles have been developed so that the readout is compatible with existing lab equipment.
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
BioForce Nanosciences develops and commercializes nanotech instruments, consumables, and applications for the life sciences. The Nano eNabler system is a molecular printer that rapidly and precisely delivers liquids to surfaces such as silicon chips in droplets that are ten billion times smaller than a drop of blood. This unique capability offers researchers in industry and academia a practical solution to problems they encounter when developing ultraminiaturized devices and methods, and creates opportunities for further commercialization of nanotechnology. For example, BioForce's technology is being used to create biosensors and to study cell biology at the single cell level. Additional applications include printing proteins to guide neural cell growth, printing signaling proteins to study stem cell differentiation, "inking" of micro-stamps for soft lithography, and bio-functionalization of microfluidic devices.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Receptor Logic is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T-Cell Receptors in the immune system. These T-Cell Receptor mimics (TCRms) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines. For more information, visit the company website www.receptorlogic.com.About Emergent Technologies, Inc.Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.